{"id":"W4415940538","doi":"10.1016/j.annonc.2025.08.978","title":"555MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment (tx) for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Final results from the phase Ib/II BEGONIA study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada); McGill University Health Centre; Santé Montérégie","funders":"AstraZeneca","keywords":"Durvalumab; Begonia; Breast cancer; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006145255,0.0005174268,0.0007952562,0.000273823,0.0001679023,0.000533174,0.0004020385,0.0003022363,0.003565613],"category_scores_gemma":[0.0002535148,0.0001774606,0.0005352561,0.0003170363,0.0002747701,0.0002916613,0.000233119,0.000902791,0.0007768698],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008515964,"about_ca_system_score_gemma":0.0008076887,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002516717,"about_ca_topic_score_gemma":0.01074368,"domain_scores_codex":[0.9998283,0.00006684363,0.000008895722,0.00002856072,0.00001697481,0.00005030622],"domain_scores_gemma":[0.9998834,0.00002053454,0.00001736523,0.00001262487,0.000005674711,0.00006027074],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3946314,0.016167,0.02211581,0.001467911,0.002945879,0.0003071145,0.000221163,0.004158907,0.06037987,0.00105783,0.01445478,0.4820924],"study_design_scores_gemma":[0.4423746,0.3435446,0.1344369,0.0003881057,0.004288594,0.001219999,0.0002355743,0.003464113,0.01371297,0.0009551731,0.05530552,0.00007375155],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9795774,0.008438461,0.000404875,0.0005148196,0.000160045,0.0005412569,0.002713812,0.0001133298,0.007535967],"genre_scores_gemma":[0.979267,0.005782272,0.00110015,0.001103961,0.00007432085,0.0003055792,0.00691183,0.00003555481,0.005419304],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003565613,"threshold_uncertainty_score":0.01192814,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1847483888090336,"score_gpt":0.5169851682150306,"score_spread":0.3322367794059969,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}